Ausgabe 4/2025
Inhalt (17 Artikel)
Bridging boundaries: from liquid biopsy in lymphoma to genomics in biliary tract cancer
- editorial
Johannes Schöche
Zolbetuximab and the novel biomarker claudin 18.2 in the treatment of gastroesophageal adenocarcinoma
- Open Access
- short review
Aysegül Ilhan-Mutlu, Florian Lordick, Ewald Wöll
Molecular profiling and targeted therapies in biliary tract cancer—a short review
- Open Access
- short review
Theresa Lentner, Hossein Taghizadeh
Proposed prognostic score including circulating free DNA concentration in diffuse large B-cell lymphoma
- original report
Esraa Jamal, Mohamed Elbogdady, Layla Saleh, Sameh Shamaah
Highlights from ASCO 2025—advances in the treatment of ovarian cancer
- Open Access
- short review
Stephan Polterauer
ASCO 2025 highlights: emerging therapies and biomarkers in pancreatic ductal adenocarcinoma
- Open Access
- short review
Hannes Windhager, Bernhard Doleschal
Chronic inflammation and cancer: ASCO 2025 update
- Open Access
- short review
Clara Dosser, Dominik Wolf, Kai Zimmer
ASCO 2025: metastatic colorectal cancer—focus on precision oncology
- Open Access
- short review
Renate Schaberl-Moser
An early twentieth-century case of lower lip cancer from the Morgagni Museum (Padua, Italy)
- original report
Alice Cusan, Maia Casna, Giovanni Magno
The role of HER2-directed antibody–drug conjugates in the treatment of metastatic breast cancer
- Open Access
- short review
Rupert Bartsch
Late toxicities and surveillance strategies after anti-CD19 and anti-BCMA CAR-T cell therapy
- short review
Natalia Rotter
Targeted therapies in advanced cholangiocarcinoma: new targets and strategies
- Open Access
- Gallenblasen- und Gallengangskarzinom
- short review
Hannes Windhager, Bernhard Doleschal
Oral therapies for unfit patients with acute myeloid leukemia
- Open Access
- short review
Verena Petzer
